RPG Life Sciences Share Price
2746.90-13.30 (-0.48%)
+12.54% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
AUROPHARMANSE
LUPINNSE
DRREDDYNSE
MANKINDNSE
RPGLIFENSE
RPG Life Sciences Share Price
2746.90-13.30 (-0.48%)
+12.54% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | - | 8% |
| - | - | - | -37% |
| 18% | 31% | 27% | 13% |
| 27% | 27% | 27% | 20% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
AUROPHARMA
LUPIN
DRREDDY
MANKIND
RPGLIFE
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,868.9 | ₹440398 Cr | 36.41 | 12.07 | 62.82 | ₹11479 Cr |
| 9,410.5 | ₹248664 Cr | 85.01 | 34.04 | 128.41 | ₹2568 Cr |
| 4,970 | ₹182738 Cr | 83.79 | 16.72 | 97.06 | ₹2163 Cr |
| 1,161 | ₹115012 Cr | 25.48 | 9.42 | 62.53 | ₹5040 Cr |
| 1,386.1 | ₹110794 Cr | 32.87 | 9.77 | 57.87 | ₹3879 Cr |
| 2,017.5 | ₹105645 Cr | 96.62 | 6.8 | 29.25 | ₹889 Cr |
| 1,713.4 | ₹99828 Cr | 26.89 | 17.95 | 96.84 | ₹3505 Cr |
| 2,124.5 | ₹98070 Cr | 17.74 | 30.95 | 154.36 | ₹5333 Cr |
| 1,198.3 | ₹97749 Cr | 30.34 | 5.32 | 63.99 | ₹4196 Cr |
| 2,437.8 | ₹95744 Cr | 46.87 | 13.75 | 71.08 | ₹1913 Cr |
| 2,769 | ₹4640 Cr | 40.29 | 18.6 | 82.62 | ₹115 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|
| ₹196 Cr | ₹177 Cr | ₹180 Cr | ₹169 Cr | ₹143 Cr | ₹173 Cr |
| ₹5 Cr | ₹12 Cr | ₹3 Cr | ₹5 Cr | ₹5 Cr | ₹3 Cr |
| ₹200 Cr | ₹189 Cr | ₹183 Cr | ₹174 Cr | ₹148 Cr | ₹176 Cr |
| ₹158 Cr | ₹150 Cr | ₹146 Cr | ₹139 Cr | ₹123 Cr | ₹129 Cr |
| ₹48 Cr | ₹45 Cr | ₹43 Cr | ₹41 Cr | ₹31 Cr | ₹52 Cr |
| ₹63 L | ₹39 L | ₹25 L | ₹13 L | ₹18 L | ₹12 L |
| ₹41 Cr | ₹40 Cr | ₹29 Cr | ₹35 Cr | ₹135 Cr | ₹47 Cr |
| ₹31 Cr | ₹30 Cr | ₹22 Cr | ₹26 Cr | ₹117 Cr | ₹35 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 |
|---|---|
| — | — |
| ₹13 Cr | ₹13 Cr |
| ₹592 Cr | ₹517 Cr |
| ₹592 Cr | ₹517 Cr |
| ₹605 Cr | ₹531 Cr |
| ₹13 Cr | ₹0 |
| ₹3 Cr | -₹1 Cr |
| ₹3 Cr | ₹3 Cr |
| ₹7 Cr | ₹5 Cr |
| ₹27 Cr | ₹6 Cr |
| — | — |
| ₹97 Cr | ₹79 Cr |
| ₹33 Cr | ₹24 Cr |
| ₹30 Cr | ₹16 Cr |
| ₹161 Cr | ₹120 Cr |
| ₹793 Cr | ₹657 Cr |
| ₹18 Cr | ₹14 Cr |
| ₹20 Cr | ₹0 |
| — | — |
| ₹321 Cr | ₹276 Cr |
| ₹125 Cr | ₹104 Cr |
| ₹197 Cr | ₹172 Cr |
| ₹20 Cr | ₹4 Cr |
| ₹1 Cr | ₹1 Cr |
| ₹1 Cr | ₹1 Cr |
| ₹13 Cr | ₹3 Cr |
| ₹234 Cr | ₹192 Cr |
| — | — |
| ₹84 Cr | ₹126 Cr |
| ₹124 Cr | ₹93 Cr |
| ₹117 Cr | ₹87 Cr |
| ₹192 Cr | ₹140 Cr |
| ₹16 Cr | ₹10 Cr |
| ₹28 Cr | ₹10 Cr |
| ₹559 Cr | ₹465 Cr |
| ₹399 Cr | ₹345 Cr |
| ₹793 Cr | ₹657 Cr |
| ₹366 | ₹321 |
| ₹366 | ₹321 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 |
|---|---|
| ₹154 Cr | ₹233 Cr |
| -₹17 Cr | -₹76 Cr |
| -₹43 Cr | -₹26 Cr |
| ₹94 Cr | ₹131 Cr |
| ₹57 Cr | ₹78 Cr |
| ₹86 Cr | -₹42 Cr |
| -₹21 Cr | -₹27 Cr |
| ₹122 Cr | ₹9 Cr |
| ₹29 Cr | ₹20 Cr |
| ₹150 Cr | ₹29 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
RPG Life Sciences Share Price
2746.90-13.30 (-0.48%)
+12.54% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 2
Bearish signals: 3 out of 9 oscillators
RSI
52.85Neutral
STOCH %K
47.80Neutral
MACD Level(12,26)
27.38Buy
Ultimate Oscillator
40.92Sell
Aroon Oscillator
-56.00Sell
BOP
-0.14Sell
CCI
53.74Neutral
Williams %R
-52.20Neutral
Momentum
156.40Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 6
Bearish signals: 3 out of 9 moving averages
EMA 9
2752.91Sell
SMA 9
2765.02Sell
EMA 21
2723.33Buy
SMA 21
2686.92Buy
EMA 50
2668.39Buy
SMA 50
2749.17Sell
EMA 200
2416.14Buy
SMA 200
2301.36Buy
WMA 20
2731.86Buy
Pivot
Pivot
Classic
Resistance 5
3109.17
Resistance 4
3026.47
Resistance 3
2943.77
Resistance 2
2861.07
Resistance 1
2810.63
Pivot
2778.37
Support 1
2727.93
Support 2
2695.67
Support 3
2612.97
Support 4
2530.27
Support 5
2447.57
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
RPG Life Sciences Share Price
2746.90-13.30 (-0.48%)
+12.54% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% |
| 0.95% | 0.87% | 1.00% | 1.11% | 1.35% | 1.46% |
| 6.62% | 5.39% | 4.98% | 1.48% | 1.09% | 0.59% |
| 0.04% | 0.04% | 0.04% | 3.20% | 3.38% | 3.53% |
| 19.44% | 20.75% | 21.03% | 21.26% | 21.23% | 21.47% |
Bulk & block deals
Name
Nk Securities Research Private Limited
Nk Securities Research Private Limited
Xtx Markets Llp
Xtx Markets Llp
Xtx Markets Llp
Xtx Markets Llp
Xtx Markets Llp
Xtx Markets Llp
Authum Investment & Infrastructure Limited
M/S Mentor Capital Limited
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 30 Apr 2026 | Purchase | 24.78 Cr | ₹2,257.02 | 1.10 L | Bulk | 0.663891 | NSE |
| 30 Apr 2026 | Sell | 24.80 Cr | ₹2,258.73 | 1.10 L | Bulk | 0.663891 | NSE |
| 21 Sep 2021 | Purchase | 9.91 Cr | ₹730.53 | 1.36 L | Bulk | 0.820533 | NSE |
| 21 Sep 2021 | Sell | 10.02 Cr | ₹731.47 | 1.37 L | Bulk | 0.827916 | NSE |
| 03 Sep 2021 | Purchase | 5.34 Cr | ₹596 | 89.62 K | Bulk | 0.541895 | NSE |
| 03 Sep 2021 | Sell | 5.11 Cr | ₹597.08 | 85.61 K | Bulk | 0.517643 | NSE |
| 01 Sep 2021 | Purchase | 9.20 Cr | ₹566.91 | 1.62 L | Bulk | 0.981456 | NSE |
| 01 Sep 2021 | Sell | 9.09 Cr | ₹568.09 | 1.60 L | Bulk | 0.967247 | NSE |
| 06 Jan 2020 | Purchase | 9.64 Cr | ₹294.31 | 3.28 L | Bulk | 1.980676 | NSE |
| 06 Jan 2020 | Sell | 9.64 Cr | ₹294.31 | 3.28 L | Bulk | 1.980676 | NSE |
Insider trading & SAST
Client name
Clarus Capital I
Nucleus Life Trust (Revised)
Nucleus Life Trust (Revised)
Nucleus Life Trust (Revised)
Nucleus Life Trust (Revised)
Nucleus Life Trust
Nucleus Life Trust
Nucleus Life Trust
Nucleus Life Trust
Nucleus Life Trust
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 May 2026 | Other | Acquisition | 0.88 | 5.41 | 0 | — | 1.45 L | 17 Apr 2026 | Market | 8,94,847 | SAST | 29(1) | — |
| 12 Mar 2025 | Promoter Group | Acquisition | 0.026676 | 53.84 | 97.38 L | ₹2,207.19 | 4.41 K | 29 Nov 2024 | Market Purchase | 89,04,393 | Insider Trading | — | Equity Shares |
| 12 Mar 2025 | Promoter Group | Acquisition | 0.00185 | 53.81 | 6.38 L | ₹2,085.73 | 306 | 28 Nov 2024 - 29 Nov 2024 | Market Purchase | 88,99,981 | Insider Trading | — | Equity Shares |
| 12 Mar 2025 | Promoter Group | Acquisition | 0.01124 | 53.81 | 39.04 L | ₹2,100.20 | 1.86 K | 28 Nov 2024 - 29 Nov 2024 | Market Purchase | 88,99,675 | Insider Trading | — | Equity Shares |
| 12 Mar 2025 | Promoter Group | Acquisition | 0.018429 | 53.86 | 66.69 L | ₹2,187.95 | 3.05 K | 29 Nov 2024 | Market Purchase | 89,07,441 | Insider Trading | — | Equity Shares |
| 26 Dec 2024 | Promoter Group | Acquisition | 0.010883 | 53.94 | 39.37 L | ₹2,187.36 | 1.80 K | 24 Dec 2024 | Market Purchase | 89,20,831 | Insider Trading | — | Equity Shares |
| 24 Dec 2024 | Promoter Group | Acquisition | 0.012165 | 53.92 | 44.17 L | ₹2,195.38 | 2.01 K | 20 Dec 2024 | Market Purchase | 89,18,137 | Insider Trading | — | Equity Shares |
| 24 Dec 2024 | Promoter Group | Acquisition | 0.005284 | 53.93 | 19 L | ₹2,174.22 | 874 | 23 Dec 2024 | Market Purchase | 89,19,021 | Insider Trading | — | Equity Shares |
| 24 Dec 2024 | Promoter Group | Acquisition | 0.00006 | 53.93 | 21.70 K | ₹2,170 | 10 | 23 Dec 2024 | Market Purchase | 89,19,031 | Insider Trading | — | Equity Shares |
| 24 Dec 2024 | Promoter Group | Acquisition | 0.00006 | 53.92 | 21.96 K | ₹2,196 | 10 | 20 Dec 2024 | Market Purchase | 89,18,147 | Insider Trading | — | Equity Shares |
RPG Life Sciences Share Price
2746.90-13.30 (-0.48%)
+12.54% past 1 Year
RPG Life Sciences a part of RPG Enterprises is an integrated pharmaceutical company operating in the domestic and international markets in the Branded Formulations Global Generics and Synthetic APIs space.
Corporate Actions
Date
Type
Details
Company details
RPG Life Sciences Share Price
2746.90-13.30 (-0.48%)
+12.54% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
RPG Life Sciences Share Price
2746.90-13.30 (-0.48%)
+12.54% past 1 Year
News
RPG Life Sciences schedules analyst and investor meeting on September 22
Equity
RPGLIFE
RPG Life Sciences plans more acquisitions to expand API portfolio
Equity
RPGLIFE
RPG Life Sciences unit to acquire Raghava Life Sciences API business
Equity
RPGLIFE
RPG Life Sciences to host analyst and investor meet on September 2
Equity
RPGLIFE
RPG Life Sciences to host analyst and investor meet on August 25
Equity
RPGLIFE
RPGLIFE Q1 EBITDA rises with improved margin performance on yearly basis
Equity
RPGLIFE
RPG Life Sciences reports strong Q1 revenue growth on year-over-year basis
Equity
RPGLIFE
RPG Life Sciences Q1 FY27 net profit rises on year, earnings snapshot
Equity
RPGLIFE
RPG Life Sciences partners Archerchem to launch Naprosyn ES pain drug in India
Equity
RPGLIFE
RPG Life Sciences partners Archerchem Healthcare to launch Naprosyn ES in India
Equity
RPGLIFE
RPG Life Sciences informs about investor conference
Equity
RPGLIFE
RPG Life Sciences Announces Dividend of Rs 24 Per Share in Corporate Results.
Equity
RPGLIFE
RPG Life Sciences Q4 EBITDA Rises 28.6% YoY to Rs 32.80 Crores, Margin Expands to 18.58%
Equity
RPGLIFE
RPG Life Sciences Q4 FY Net Profit Declines 75% YoY to Rs 29.90 Crores
Equity
RPGLIFE
RPG Life Sciences reports Profit after tax of 29.90 Crores, in the March 2026 quarter
Equity
RPGLIFE
RPG Life Sciences informs about investor presentation
Equity
RPGLIFE
RPG Life Sciences Sees Strong January API Performance and Robust Domestic Portfolio per CNBC-TV18.
Equity
RPGLIFE
RPG Life Sciences - Quaterly Results
Equity
RPGLIFE
RPG Life Sciences Q3 EBITDA Declines 19% YoY to Rs 39.80 Crores, Margin Contracts to 22.09%.
Equity
RPGLIFE
RPG Life Sciences Q3 FY2025 Results: Net Profit Surge Amid Revenue Growth
Equity
RPGLIFE

